First Tracks reports positive results for celiac treatment trial

what happened

Dow Jones Newswires reported that First Tracks Biotherapeutics released positive top-line findings from an early-stage study of ANB033, its treatment for celiac disease. The company said the therapy produced a statistically significant and clinically meaningful protective effect compared with placebo, addressing both gluten-related intestinal damage and disease symptoms.

During the study, patients completed a 14-day gluten challenge involving an amount equivalent to two slices of bread each day. First Tracks said ANB033 kept symptoms from worsening across the full challenge, while participants given placebo showed a marked increase consistent with a severe gluten exposure. The company also described the treatment’s safety profile as favorable.

First Tracks shares rose 17% to $37.36 in premarket trading. Chief Executive Daniel Faga said the company plans to continue working with regulators, clinicians and the patient community as it moves ANB033 toward late-stage development in 2027.

why it matters

The early trial data lifted First Tracks shares in premarket trading and outlined the company’s plan to advance ANB033 into late-stage development in 2027.

instruments